Form 4: Amylyx Pharmaceuticals CFO James M. Frates Acquires 40,000 Shares

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, recently purchased 40,000 shares of the company's common stock at an average price of $2.5342.

Summary

• On September 12, 2024, James M. Frates, the CFO of Amylyx Pharmaceuticals, acquired 40,000 shares of common stock.
• The purchase was made at a weighted average price of $2.5342 per share, with individual transactions ranging from $2.4849 to $2.63.
• Following the transaction, Frates directly owns 233,464 shares.
• Frates also indirectly owns 15,459 shares through the James M. Frates 2024 Grantor Retained Annuity Trust No. 1 and 11,072 shares through the FRATES FAMILY 2013 IRREV TRUST, for which he serves as trustee.
• He disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CFO's purchase suggests confidence, but it's a single transaction and doesn't provide definitive insight into the company's overall health.

Positives

• The CFO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the transactions of key personnel.

Comparison to Industry Standards

• Insider trading activity is closely monitored in the pharmaceutical industry, as it can provide insights into the perceived value and future prospects of a company.
• Comparing Frates' trading activity to that of other executives in similar-sized pharmaceutical companies could provide a benchmark for assessing the significance of this transaction.

Stakeholder Impact

• The CFO's stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates